Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed stage IIIA or IIIB non-small cell lung cancer (NSCLC) with
one of the following p53 mutations:

- Point mutation altering the protein sequence

- Frame-shift mutation with the generation of a novel sequence

- No significant pleural effusions visible on plain chest radiography

- Must have completed or plan to undergo curative intent therapy for NSCLC

- At least 2 courses of neoadjuvant chemotherapy for patients with known N2 or N3
resectable disease OR

- At least 55 Gy radiotherapy with concurrent or sequential chemotherapy for
patients with unresectable disease

- Patients with incidental N2 or N3 disease at time of surgery may receive
optional adjuvant chemotherapy and radiotherapy

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- ECOG 0-1

Life expectancy:

- Not specified

Hematopoietic:

- Lymphocyte count greater than 475/mm^3

- Granulocyte count greater than 1,000/mm^3

- Platelet count greater than 100,000/mm^3

Hepatic:

- Bilirubin less than 2.0 mg/dL

- SGOT less than 3 times normal

- Albumin at least 3.0 g/dL

- No signs of acute hepatitis B infection

- Hepatitis B surface antigen positive allowed provided there are no signs of
chronic active hepatitis

- No prior hepatitis C infection

Renal:

- Creatinine less than 2.5 mg/dL

- Calcium less than 11.0 mg/dL (corrected for albumin)

Cardiovascular:

- No myocardial infarction or significant ventricular arrhythmias within the past 6
months

Other:

- No other malignancy within the past 5 years unless curatively treated and probability
of recurrence is less than 5%

- HIV negative

- No psychiatric or other condition that would preclude study

- No serious ongoing infection

- No other serious medical condition that would limit life expectancy to less than 2
years

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy and no anticipated need for chemotherapy
for at least 2 months after vaccinations

Endocrine therapy:

- At least 4 weeks since prior supraphysiologic steroids and no anticipated need for
steroid therapy for at least 2 months after vaccinations

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and no anticipated need for radiotherapy
for at least 2 months after vaccinations

Surgery:

- See Disease Characteristics

Other:

- No influenza vaccination if egg allergy present

- At least 4 weeks and no greater than 24 weeks since completion of all prior
modalities for primary therapy